Rocket Pharmaceuticals, Inc.

NasdaqGM:RCKT 株式レポート

時価総額：US$1.3b

Rocket Pharmaceuticals マネジメント

マネジメント 基準チェック /24

Rocket Pharmaceuticalsの CEO はGaurav Shahで、 Jan2018年に任命され、 の在任期間は 6.83年です。 の年間総報酬は$ 8.01Mで、 7.8%給与と92.2%のボーナス（会社の株式とオプションを含む）で構成されています。 は、会社の株式の1.22%を直接所有しており、その価値は$ 15.71M 。経営陣と取締役会の平均在任期間はそれぞれ3.2年と6.8年です。

主要情報

Gaurav Shah

最高経営責任者

US$8.0m

報酬総額

CEO給与比率7.8%
CEO在任期間6.8yrs
CEOの所有権1.2%
経営陣の平均在職期間3.2yrs
取締役会の平均在任期間6.8yrs

経営陣の近況

Recent updates

Will Rocket Pharmaceuticals (NASDAQ:RCKT) Spend Its Cash Wisely?

Sep 23
Will Rocket Pharmaceuticals (NASDAQ:RCKT) Spend Its Cash Wisely?

Rocket Pharmaceuticals: 2 Gene Therapy Candidates Anticipating Near-Term Review

Sep 15

Rocket Pharmaceuticals: CRL For Kresladi Unwelcome, But Likely A Quick Fix

Jun 28

We're Hopeful That Rocket Pharmaceuticals (NASDAQ:RCKT) Will Use Its Cash Wisely

Jun 09
We're Hopeful That Rocket Pharmaceuticals (NASDAQ:RCKT) Will Use Its Cash Wisely

Rocket Pharmaceuticals: Cautiously Optimistic (Rating Upgrade)

Apr 05

Rocket Pharmaceuticals' Promising Path In Gene Therapy

Mar 01

Companies Like Rocket Pharmaceuticals (NASDAQ:RCKT) Are In A Position To Invest In Growth

Nov 07
Companies Like Rocket Pharmaceuticals (NASDAQ:RCKT) Are In A Position To Invest In Growth

Rocket Pharmaceuticals slides over 6% after hours on $100M stock offering

Oct 03

Rocket Pharmaceuticals: Updates To Thesis, Clinical Momentum Continues To Accelerate

Aug 25

We're Not Very Worried About Rocket Pharmaceuticals' (NASDAQ:RCKT) Cash Burn Rate

Jul 22
We're Not Very Worried About Rocket Pharmaceuticals' (NASDAQ:RCKT) Cash Burn Rate

Rocket Pharmaceuticals an outperform at Raymond James on gene therapy programs

Jul 08

Rocket Pharma: Poised For Growth In The Rare Disease Space

Jun 30

Rocket Pharmaceuticals: A Struggling Company With Long-Term Upside

Jan 30

We're Hopeful That Rocket Pharmaceuticals (NASDAQ:RCKT) Will Use Its Cash Wisely

Nov 09
We're Hopeful That Rocket Pharmaceuticals (NASDAQ:RCKT) Will Use Its Cash Wisely

Rocket Pharmaceuticals Stock Forecast: Can It Rebound To $50 Levels? A Resounding Yes

Oct 01

Rocket earns Evercore nod after positive data for rare genetic disease

Dec 17

Rocket Pharma +33.6% after positive early data in Danon disease Phase 1 trial

Dec 09

CEO報酬分析

Rocket Pharmaceuticals の収益と比較して、Gaurav Shah の報酬はどのように変化したか？
日付総報酬給与会社業績
Sep 30 2024n/an/a

-US$258m

Jun 30 2024n/an/a

-US$253m

Mar 31 2024n/an/a

-US$249m

Dec 31 2023US$8mUS$625k

-US$246m

Sep 30 2023n/an/a

-US$253m

Jun 30 2023n/an/a

-US$249m

Mar 31 2023n/an/a

-US$237m

Dec 31 2022US$7mUS$598k

-US$222m

Sep 30 2022n/an/a

-US$199m

Jun 30 2022n/an/a

-US$192m

Mar 31 2022n/an/a

-US$172m

Dec 31 2021US$8mUS$590k

-US$169m

Sep 30 2021n/an/a

-US$186m

Jun 30 2021n/an/a

-US$165m

Mar 31 2021n/an/a

-US$155m

Dec 31 2020US$7mUS$540k

-US$140m

Sep 30 2020n/an/a

-US$99m

Jun 30 2020n/an/a

-US$89m

Mar 31 2020n/an/a

-US$82m

Dec 31 2019US$4mUS$480k

-US$77m

Sep 30 2019n/an/a

-US$85m

Jun 30 2019n/an/a

-US$82m

Mar 31 2019n/an/a

-US$79m

Dec 31 2018US$6mUS$414k

-US$75m

報酬と市場: Gauravの 総報酬 ($USD 8.01M ) は、 US市場 ($USD 5.42M ) の同規模の企業の平均を上回っています。

報酬と収益: Gauravの報酬は増加しましたが、会社は利益を上げていません。

CEO（最高経営責任者

Gaurav Shah (49 yo)

6.8yrs

在職期間

US$8,013,553

報酬

Dr. Gaurav D. Shah, M.D., has been an Independent Director at Talaris Therapeutics, Inc. since December 2020. He serves as the Chief Executive Officer and Director of Rocket Pharmaceuticals, Ltd since Janu...

リーダーシップ・チーム

名称ポジション在職期間報酬所有権
Gaurav Shah
CEO & Director6.8yrsUS$8.01m1.22%
$ 15.7m
Kinnari Patel
Head of R&D6.8yrsUS$4.85m0.44%
$ 5.7m
Mayo Pujols
Chief Technical Officer2.3yrsUS$4.38m0.062%
$ 799.0k
Jonathan Schwartz
Chief Medical & Gene Therapy Officer6.8yrsUS$3.16m0.11%
$ 1.4m
Aaron Ondrey
Chief Financial Officerless than a yearデータなしデータなし
Martin Wilson
General Counsel3yrsUS$1.56m0.070%
$ 896.9k
Kevin Giordano
Director of Corporate Communicationsno dataデータなしデータなし
Isabel Carmona
Chief People Officer3.2yrsデータなしデータなし
Gayatri Rao
Senior VP of Clinical Safety & Chief Regulatory Officer4.6yrsデータなしデータなし
Raj Prabhakar
Chief Business Officerno dataUS$2.82m0%
$ 0
Carlos Martin
Chief Commercial Operations & Revenue Officerless than a yearデータなしデータなし

3.2yrs

平均在職期間

49yo

平均年齢

経験豊富な経営陣: RCKTの経営陣は 経験豊富 であると考えられます ( 3.2年の平均在職年数)。

取締役

名称ポジション在職期間報酬所有権
Gaurav Shah
CEO & Director6.8yrsUS$8.01m1.22%
$ 15.7m
David Southwell
Independent Director10.3yrsUS$399.99k0.13%
$ 1.6m
Pedro Granadillo
Independent Director6.8yrsUS$429.98k0%
$ 0
Carsten Boess
Independent Director8.8yrsUS$427.49k0%
$ 0
Mikael Dolsten
Independent Directorless than a yearデータなしデータなし
Roderick Tze Wong
Chairman of the Board6.8yrsUS$409.99k0.059%
$ 756.6k
Naveen Yalamanchi
Independent Director6.8yrsUS$417.49k0.13%
$ 1.6m
Fady Malik
Independent Non-Executive Director2.7yrsUS$399.99k0%
$ 0
Elisabeth Bjork
Independent Director4.6yrsUS$409.99k0%
$ 0
Gotham Makker
Director6.8yrsUS$399.99k0.22%
$ 2.8m
Robert Woods
Independent Non- Executive Directorless than a yearUS$568.70kデータなし

6.8yrs

平均在職期間

58yo

平均年齢

経験豊富なボード: RCKTの 取締役会 は 経験豊富 であると考えられます ( 6.8年の平均在任期間)。